# Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?

> **NCT03227562** · PHASE3 · TERMINATED · sponsor: **Marion Trousselard** · enrollment: 120 (actual)

## Conditions studied

- Anxiety State

## Interventions

- **DRUG:** RisperiDONE 0.5 MG

## Key facts

- **NCT ID:** NCT03227562
- **Lead sponsor:** Marion Trousselard
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-01
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** not enough patient
- **Last updated:** 2022-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03227562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03227562, "Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03227562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*